title: Novel therapies for Hodgkin Lymphoma.
abstract: In recent years, improved understanding of the biology of Hodgkin Lymphoma (HL) has uncovered many potential targets for the treatment of this disease. Clarification of the B-ceLL origin of the Hodgkin Reed Sternberg (HRS) cell and of the complex interactions between the HRS cell and the HL microenvironment have provided new insights into the pathophysiology of HL and identified extracellular and intracellular molecules which are essential for HRS survival. New agents directed at these molecules are now in early phase clinical trials.
authors.forename: John W
authors.initials: JW
authors.lastname: Sweetenham
keywords: Hodgkin Lymphoma; new agents; targeted therapy
references.citation: J Clin Oncol. 2005 Jul 20;23(21):4634-42
references.pmid: 15837968
references.citation: Clin Cancer Res. 2002 Jun;8(6):1779-86
references.pmid: 12060617
references.citation: Blood. 2006 Feb 15;107(4):1731-2
references.pmid: 16461762
references.citation: J Clin Oncol. 2007 Jul 1;25(19):2764-9
references.pmid: 17515574
references.citation: Blood. 2008 Jan 1;111(1):109-11
references.pmid: 17938252
references.citation: Cancer Res. 2003 Jul 1;63(13):3637-45
references.pmid: 12839953
references.citation: Blood. 2001 Feb 1;97(3):616-23
references.pmid: 11157476
references.citation: Cancer. 2003 Jul 15;98(2):310-4
references.pmid: 12872350
references.citation: Clin Cancer Res. 2001 Jul;7(7):1873-81
references.pmid: 11448899
references.citation: Br J Haematol. 2010 Feb;148(3):480-2
references.pmid: 19863533
references.citation: Blood. 2009 Jun 18;113(25):6392-402
references.pmid: 19377047
references.citation: Blood. 2005 Jun 15;105(12):4553-60
references.pmid: 15728122
references.citation: Blood. 2004 Mar 1;103(5):1755-62
references.pmid: 14604957
references.citation: Proc Natl Acad Sci U S A. 2004 Apr 27;101(17):6611-6
references.pmid: 15096587
references.citation: Blood. 2005 Sep 1;106(5):1839-42
references.pmid: 15878978
references.citation: Br J Haematol. 2009 Jul;146(2):171-9
references.pmid: 19466965
references.citation: J Exp Med. 2003 Jul 21;198(2):341-7
references.pmid: 12874265
references.citation: J Clin Oncol. 2003 Oct 1;21(19):3601-8
references.pmid: 12913100
references.citation: Am J Surg Pathol. 2005 Feb;29(2):196-203
references.pmid: 15644776
references.citation: J Exp Med. 2004 Dec 20;200(12):1623-33
references.pmid: 15611290
references.citation: J Clin Oncol. 2009 Sep 20;27(27):4548-54
references.pmid: 19704068
references.citation: Am J Pathol. 1999 Jun;154(6):1685-91
references.pmid: 10362793
references.citation: Br J Haematol. 2005 Aug;130(4):501-10
references.pmid: 16098063
references.citation: Haematologica. 2006 Apr;91(4):475-81
references.pmid: 16585014
references.citation: Blood. 2003 Jun 1;101(11):4285-9
references.pmid: 12586628
references.citation: Exp Hematol. 2000 Jan;28(1):31-5
references.pmid: 10658674
references.citation: Leuk Lymphoma. 2007 Jul;48(7):1313-9
references.pmid: 17613759
references.citation: Leuk Lymphoma. 1997 Oct;27(3-4):195-205
references.pmid: 9402319
references.citation: Blood. 2003 Aug 1;102(3):1019-27
references.pmid: 12689928
references.citation: Cancer. 2004 May 1;100(9):1892-901
references.pmid: 15112270
references.citation: J Clin Oncol. 2006 Jul 1;24(19):3128-35
references.pmid: 16754934
references.citation: J Exp Med. 2004 Apr 19;199(8):1041-52
references.pmid: 15078899
references.citation: Blood. 2002 Nov 1;100(9):3101-7
references.pmid: 12384405